The National Institute for Health and Clinical Excellence (NICE) is no stranger
to controversy, but rarely have their decisions ignited such heated debate as their
recommendation of drugs to treat dementia. Professor Clive Ballard and Samantha Sharp
of the Alzheimer’s Society study the data, marshall their thoughts and articulate concerns
about the new recommendations.